Efficacy and safety of anamorelin in patients with metastatic urothelial carcinoma receiving systemic chemotherapy: a randomized controlled study

What Was Tested

This randomized controlled trial paper looks at Anamorelin (non-peptide).

Who Took Part

The abstract describes 38 patients taking part.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

A total of 38 patients with mUC who received platinum-based chemotherapy were enrolled in an interventional prospective study.

Patients were randomized to anamorelin (Ana; n = 20) or control (n = 18) groups.

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Anamorelin (non-peptide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The primary endpoint was the change in prealbumin.

Secondary endpoints were changes in albumin, IGF-1, body weight, skeletal muscle mass index (SMI), interleukin-6 (IL-6) and median overall survival (mOS).

What Was Measured

The subject headings attached to it are Insulin-Like Growth Factor I, Neoplasm Metastasis, Interleukin-6, Antineoplastic Combined Chemotherapy Protocols and Cachexia.

The authors tagged it with the keywords anamorelin, cancer cachexia, insulin-like growth factor 1, systemic chemotherapy and urothelial carcinoma.

What This Means in Plain Language

The paper is a randomized study of Anamorelin (non-peptide) in 38 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2025 (The oncologist), a journal based in England.

More context: the Anamorelin (non-peptide) compound page, all human trials.